INNOVADERM CRO IS NOW INDERO.

Putting Patients First in Clinical Trials

Julie Massicotte

Julie Massicotte

Senior Director, Regulatory Affairs

Author picture

In the article “Putting Patients First in Clinical Trials,” published by Pharmaceutical Processing World, Julie Massicotte, Senior Director of Regulatory Affairs at Indero, emphasizes:

  • The importance of prioritizing patient needs and experiences in clinical research. The piece discusses how involving patients in the design and implementation of trials can lead to more relevant and broadly applicable research outcomes.
  • Massicotte highlights strategies for improving patient recruitment, retention, and engagement, ensuring that trials are both effective and patient-centered.

For a detailed exploration of how patient-centric approaches can transform clinical trials, read the full article here:
  Read More

SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

Jeff Smith

Chef de la direction

Jeff Smith, Chef de la direction d’Indero Recherches, apporte près de 30 ans d’expérience dans l’industrie pharmaceutique et CRO, s’étant distingué par son leadership exceptionnel, sa vision stratégique et son innovation. L’expertise de Jeff couvre des opérations mondiales, la gestion de la croissance, ainsi que la promotion d’une culture d’entreprise collaborative. Ses atouts en matière de création de valeur, de gestion des partenaires et d’opérations CRO ont toujours contribué au succès dans ses fonctions précédentes. Sous la direction de Jeff, Indero continue d’étendre ses capacités, faisant progresser les connaissances médicales et les nouvelles thérapies en dermatologie et en rhumatologie.

Revolutionize Your Topical Trials

Efficacy insights in days, not months.

 Indero’s Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8–12 weeks to ≤3 days, and lowers costs, helping teams make informed go/no-go decisions faster.